Real-world study shows low remission rates in GC-refractory MAS

The AMETHYST retrospective cohort study examined treatment patterns and outcomes in 64 patients with glucocorticoid-refractory macrophage activation syndrome (MAS) complicating Still's disease across eight sites in Europe, Canada, and the US. All patients received glucocorticoids, with most also treated with anakinra and/or ciclosporin; the study reported complete laboratory remission in only 10.9% of patients, MAS recurrence in 31.3%, and seven deaths (1-year survival probability 93.75%). The authors state these findings highlight a need for safer, more effective therapies given low remission rates and toxicities associated with high-dose glucocorticoid combination treatment.

Most relevant for: Patients with systemic juvenile idiopathic arthritis or adult-onset Still's disease who develop glucocorticoid-refractory macrophage activation syndrome.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.